Skip to content
2000
Volume 5, Issue 1
  • ISSN: 0250-6882
  • E-ISSN: 0250-6882
side by side viewer icon HTML

Abstract

Pulmonary hypertension (PH) is a progressive disease characterized by elevation of pulmonary arterial pressure over 25mmHg. PH has become a global issue associated with substantial morbidity and mortality despite the emergence of several treatment options in the last two decades.

The Emirates Thoracic Society, Emirates Rheumatology Society, and Emirates Cardiac Society took up the task of coming up with regional practical recommendations. The recommendations were formulated based on a careful consideration of scientific and medical knowledge and the evidence available at the time of publication. All endeavors were directed towards making the updated guideline handy for practicing clinicians in the region involved in the management of patients with PH.

This article highlights the updated guidelines in a reader-friendly format and highlights the recent updates made by the 6th World Symposium on Pulmonary Hypertension and the updated ESC ERS 2022 guidelines on PH with regards to classification. Group 1 sub-group has been further classified into “definitive” and “possible” with the inclusion of sub-group “pulmonary arterial hypertension (PAH) long-term responders to calcium channel blockers” and “PAH with overt features of venous/capillaries (pulmonary veno-occlusive disease/ pulmonary capillary haemangiomatosis) involvement”. Group 2.1 was re-named “PH due to heart failure with preserved left ventricular ejection fraction” and Group 2.2 was re-named “PH due to heart failure with reduced left ventricular ejection fraction”. Group 5 has two major updates: (i) removing splenectomy and thyroid disorders, and (ii) the classification of LAM-associated PH together with other parenchymal lung diseases in group 3.

This article highlights the clinical classification updates and the gaps and challenges associated with genetic testing in the region.

This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Loading

Article metrics loading...

/content/journals/nemj/10.2174/0102506882331838241122172040
2024-01-01
2025-07-06
The full text of this item is not currently available.

References

  1. HoeperM.M. HumbertM. SouzaR. IdreesM. KawutS.M. Sliwa-HahnleK. JingZ.C. GibbsJ.S.R. A global view of pulmonary hypertension.Lancet Respir. Med.20164430632210.1016/S2213‑2600(15)00543‑326975810
    [Google Scholar]
  2. VaveraZ. VojacekJ. PudilR. MalyJ. EliasP. Chronic thromboembolic pulmonary hypertension after the first episode of pulmonary embolism? How often?Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub.2016160112512910.5507/bp.2015.02126006091
    [Google Scholar]
  3. KlokF.A. TescheC. RappoldL. DellasC. HasenfußG. HuismanM.V. KonstantinidesS. LankeitM. External validation of a simple non-invasive algorithm to rule out chronic thromboembolic pulmonary hypertension after acute pulmonary embolism.Thromb. Res.2015135579680110.1016/j.thromres.2014.12.00925746363
    [Google Scholar]
  4. Kayaalpİ. VarolY. ÇimenP. Demirci ÜçsularF. KatgiN. ÜnlüM. KıraklıC. GüçlüS.Z. ErgeneO. The incidence of chronic thromboembolic pulmonary hypertension secondary to acute pulmonary thromboembolism.Tuberk. Toraks201462319920610.5578/tt.771725492817
    [Google Scholar]
  5. SimonneauG. TorbickiA. DorfmüllerP. KimN. The pathophysiology of chronic thromboembolic pulmonary hypertension.Eur. Respir. Rev.20172614316011210.1183/16000617.0112‑201628356405
    [Google Scholar]
  6. FreitasC.S.G. BaldiB.G. JardimC. AraujoM.S. SobralJ.B. HeidenG.I. KairallaR.A. SouzaR. CarvalhoC.R.R. Pulmonary hypertension in lymphangioleiomyomatosis: prevalence, severity and the role of carbon monoxide diffusion capacity as a screening method.Orphanet J. Rare Dis.20171217410.1186/s13023‑017‑0626‑028427470
    [Google Scholar]
  7. FonsecaG.H.H. SouzaR. SalemiV.M.C. JardimC.V.P. GualandroS.F.M. Pulmonary hypertension diagnosed by right heart catheterisation in sickle cell disease.Eur. Respir. J.201239111211810.1183/09031936.0013441021778170
    [Google Scholar]
  8. ParentF. BachirD. InamoJ. LionnetF. DrissF. LokoG. HabibiA. BennaniS. SavaleL. AdnotS. MaitreB. YaïciA. HajjiL. O’CallaghanD.S. ClersonP. GirotR. GalacterosF. SimonneauG. A hemodynamic study of pulmonary hypertension in sickle cell disease.N. Engl. J. Med.20113651445310.1056/NEJMoa100556521732836
    [Google Scholar]
  9. MehariA. GladwinM.T. TianX. MachadoR.F. KatoG.J. Mortality in adults with sickle cell disease and pulmonary hypertension.JAMA2012307121254125610.1001/jama.2012.35822453563
    [Google Scholar]
  10. MarínM.J.C. RotésA.S. OgandoA.R. SotoA.M. JiménezM.Q. CamachoJ.L.G. SonnenfeldI.R. BonoraA.M. BrotonsD.C.A. GaldóA.M. Assessing pulmonary hypertensive vascular disease in childhood. Data from the Spanish registry.Am. J. Respir. Crit. Care Med.2014190121421142910.1164/rccm.201406‑1052OC25379685
    [Google Scholar]
  11. van LoonR.L.E. RoofthooftM.T.R. HillegeH.L. ten HarkelA.D.J. van Osch-GeversM. DelhaasT. KapustaL. StrengersJ.L.M. RammelooL. ClurS.A.B. MulderB.J.M. BergerR.M.F. Pediatric pulmonary hypertension in the Netherlands: epidemiology and characterization during the period 1991 to 2005.Circulation2011124161755176410.1161/CIRCULATIONAHA.110.96958421947294
    [Google Scholar]
  12. LiL. JickS. BreitensteinS. HernandezG. MichelA. VizcayaD. Pulmonary arterial hypertension in the USA: an epidemiological study in a large insured pediatric population.Pulm. Circ.20177112613610.1086/69000728680572
    [Google Scholar]
  13. UnegbuC. NojeC. CoulsonJ.D. SegalJ.B. RomerL. Pulmonary Hypertension Therapy and a Systematic Review of Efficacy and Safety of PDE-5 Inhibitors.Pediatrics20171393e2016145010.1542/peds.2016‑145028235796
    [Google Scholar]
  14. ArjaansS. ZwartE.A.H. PloegstraM.J. BosA.F. KooiE.M.W. HillegeH.L. BergerR.M.F. Identification of gaps in the current knowledge on pulmonary hypertension in extremely preterm infants: A systematic review and meta-analysis.Paediatr. Perinat. Epidemiol.201832325826710.1111/ppe.1244429341209
    [Google Scholar]
  15. KovacsG. BergholdA. ScheidlS. OlschewskiH. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review.Eur. Respir. J.200934488889410.1183/09031936.0014560819324955
    [Google Scholar]
  16. ValerioC.J. SchreiberB.E. HandlerC.E. DentonC.P. CoghlanJ.G. Borderline mean pulmonary artery pressure in patients with systemic sclerosis: transpulmonary gradient predicts risk of developing pulmonary hypertension.Arthritis Rheum.20136541074108410.1002/art.3783823280155
    [Google Scholar]
  17. CoghlanJ.G. WolfM. DistlerO. DentonC.P. DoelbergM. HarutyunovaS. MarraA.M. BenjaminN. FischerC. GrünigE. Incidence of pulmonary hypertension and determining factors in patients with systemic sclerosis.Eur. Respir. J.2018514170119710.1183/13993003.01197‑201729563168
    [Google Scholar]
  18. DouschanP. KovacsG. AvianA. ForisV. GruberF. OlschewskiA. OlschewskiH. Mild Elevation of Pulmonary Arterial Pressure as a Predictor of Mortality.Am. J. Respir. Crit. Care Med.2018197450951610.1164/rccm.201706‑1215OC29099619
    [Google Scholar]
  19. TaboadaD. Pepke-ZabaJ. JenkinsD.P. BermanM. TreacyC.M. CannonJ.E. ToshnerM. DunningJ.J. NgC. TsuiS.S. ShearesK.K. Outcome of pulmonary endarterectomy in symptomatic chronic thromboembolic disease.Eur. Respir. J.20144461635164510.1183/09031936.0005011425234805
    [Google Scholar]
  20. Olgun YıldızeliŞ. KepezA. TaşS. YanartaşM. DurusoyA.F. ErkılınçA. MutluB. KaymazC. SunarH. YıldızeliB. Pulmonary endarterectomy for patients with chronic thromboembolic disease.Anatol. J. Cardiol.201819427327829615545
    [Google Scholar]
  21. HoeperM.M. BogaardH.J. CondliffeR. FrantzR. KhannaD. KurzynaM. LanglebenD. ManesA. SatohT. TorresF. WilkinsM.R. BadeschD.B. Definitions and diagnosis of pulmonary hypertension.J. Am. Coll. Cardiol.20136225Suppl.D42D5010.1016/j.jacc.2013.10.03224355641
    [Google Scholar]
  22. GalièN. HumbertM. VachieryJ.L. GibbsS. LangI. TorbickiA. SimonneauG. PeacockA. Vonk NoordegraafA. BeghettiM. GhofraniA. Gomez SanchezM.A. HansmannG. KlepetkoW. LancellottiP. MatucciM. McDonaghT. PierardL.A. TrindadeP.T. ZompatoriM. HoeperM. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.Eur. Heart J.20163716711910.1093/eurheartj/ehv31726320113
    [Google Scholar]
  23. TedfordR.J. BeatyC.A. MathaiS.C. KolbT.M. DamicoR. HassounP.M. LearyP.J. KassD.A. ShahA.S. Prognostic value of the pre-transplant diastolic pulmonary artery pressure-to-pulmonary capillary wedge pressure gradient in cardiac transplant recipients with pulmonary hypertension.J. Heart Lung Transplant.201433328929710.1016/j.healun.2013.11.00824462554
    [Google Scholar]
  24. ChaouatA. BugnetA.S. KadaouiN. SchottR. EnacheI. DucolonéA. EhrhartM. KesslerR. WeitzenblumE. Severe pulmonary hypertension and chronic obstructive pulmonary disease.Am. J. Respir. Crit. Care Med.2005172218919410.1164/rccm.200401‑006OC15831842
    [Google Scholar]
  25. WeitzenblumE. ChaouatA. CanuetM. KesslerR. Pulmonary hypertension in chronic obstructive pulmonary disease and interstitial lung diseases.Semin. Respir. Crit. Care Med.200930445847010.1055/s‑0029‑123331519634085
    [Google Scholar]
  26. BishopJ.M. CrossK.W. Physiological variables and mortality in patients with various categories of chronic respiratory disease.Bull. Eur. Physiopathol. Respir.19842064955006440605
    [Google Scholar]
  27. Pepke-ZabaJ. DelcroixM. LangI. MayerE. JansaP. AmbrozD. TreacyC. D’ArminiA.M. MorsoliniM. SnijderR. BresserP. TorbickiA. KristensenB. LewczukJ. SimkovaI. BarberàJ.A. de PerrotM. HoeperM.M. GaineS. SpeichR. Gomez-SanchezM.A. KovacsG. HamidA.M. JaïsX. SimonneauG. Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry.Circulation2011124181973198110.1161/CIRCULATIONAHA.110.01500821969018
    [Google Scholar]
  28. HumbertM. KovacsG. HoeperM.M. BadagliaccaR. BergerR.M.F. BridaM. CarlsenJ. CoatsA.J.S. Escribano-SubiasP. FerrariP. FerreiraD.S. GhofraniH.A. GiannakoulasG. KielyD.G. MayerE. MeszarosG. NagavciB. OlssonK.M. Pepke-ZabaJ. QuintJ.K. RådegranG. SimonneauG. SitbonO. ToniaT. ToshnerM. VachieryJ.L. Vonk NoordegraafA. DelcroixM. RosenkranzS. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.Eur. Respir. J.2023611220087910.1183/13993003.00879‑202236028254
    [Google Scholar]
  29. GalièN. McLaughlinV.V. RubinL.J. SimonneauG. An overview of the 6th World Symposium on Pulmonary Hypertension.Eur. Respir. J.2019531180214810.1183/13993003.02148‑201830552088
    [Google Scholar]
  30. SimonneauG. MontaniD. CelermajerD.S. DentonC.P. GatzoulisM.A. KrowkaM. WilliamsP.G. SouzaR. Haemodynamic definitions and updated clinical classification of pulmonary hypertension.Eur. Respir. J.2019531180191310.1183/13993003.01913‑201830545968
    [Google Scholar]
  31. MontaniD. BergotE. GüntherS. SavaleL. BergeronA. BourdinA. BouvaistH. CanuetM. PisonC. MacroM. PoubeauP. GirerdB. NataliD. GuignabertC. PerrosF. O’CallaghanD.S. JaïsX. Tubert-BitterP. ZalcmanG. SitbonO. SimonneauG. HumbertM. Pulmonary arterial hypertension in patients treated by dasatinib.Circulation2012125172128213710.1161/CIRCULATIONAHA.111.07992122451584
    [Google Scholar]
  32. WeatheraldJ. ChaumaisM.C. SavaleL. JaïsX. SeferianA. CanuetM. BouvaistH. MagroP. BergeronA. GuignabertC. SitbonO. SimonneauG. HumbertM. MontaniD. Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study.Eur. Respir. J.2017501170021710.1183/13993003.00217‑201728751413
    [Google Scholar]
  33. ZamanianR.T. HedlinH. GreuenwaldP. WilsonD.M. SegalJ.I. JordenM. KudelkoK. LiuJ. HsiA. RuppA. SweattA.J. TuderR. BerryG.J. RabinovitchM. DoyleR.L. de Jesus PerezV. KawutS.M. Features and Outcomes of Methamphetamine-associated Pulmonary Arterial Hypertension.Am. J. Respir. Crit. Care Med.2018197678880010.1164/rccm.201705‑0943OC28934596
    [Google Scholar]
  34. HickeyP.M. ThompsonA.A.R. CharalampopoulosA. ElliotC.A. HamiltonN. KielyD.G. LawrieA. SabroeI. CondliffeR. Bosutinib therapy resulting in severe deterioration of pre-existing pulmonary arterial hypertension.Eur. Respir. J.20164851514151610.1183/13993003.01004‑201627660511
    [Google Scholar]
  35. SeegobinK. BabbarA. FerreiraJ. LyonsB. CuryJ. SeeramV. A case of worsening pulmonary arterial hypertension and pleural effusions by bosutinib after prior treatment with dasatinib.Pulm. Circ.20177480881210.1177/204589321773344428914582
    [Google Scholar]
  36. RiouM. SeferianA. SavaleL. ChaumaisM.C. GuignabertC. CanuetM. MagroP. ReaD. SitbonO. JaïsX. HumbertM. MontaniD. Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicity.Eur. Respir. J.20164851517151910.1183/13993003.01410‑201627799395
    [Google Scholar]
  37. RenardS. BorentainP. SalaunE. BenhaourechS. MailleB. DarqueA. BregigeonS. ColsonP. LaugierD. Reynaud GaubertM. HabibG. Severe Pulmonary Arterial Hypertension in Patients Treated for Hepatitis C With Sofosbuvir.Chest20161493e69e7310.1016/j.chest.2015.09.01826965976
    [Google Scholar]
  38. AlvarezP.A. SaadA.K. FlagelS. MazzocchiO. BlancoM.V. Leflunomide-induced pulmonary hypertension in a young woman with rheumatoid arthritis: a case report.Cardiovasc. Toxicol.201212218018310.1007/s12012‑012‑9153‑322270725
    [Google Scholar]
  39. CoirierV. LescoatA. ChabanneC. FournetM. CoiffierG. JouneauS. PolardE. JégoP. Pulmonary arterial hypertension in four patients treated by leflunomide.Joint Bone Spine201885676176310.1016/j.jbspin.2017.12.01429329993
    [Google Scholar]
  40. Martinez-TaboadaV.M. Rodriguez-ValverdeV. Gonzalez-VilchezF. ArmijoJ.A. Pulmonary hypertension in a patient with rheumatoid arthritis treated with leflunomide.Br. J. Rheumatol.200443111451145210.1093/rheumatology/keh32815501999
    [Google Scholar]
  41. MisumiK. OgoT. UedaJ. TsujiA. FukuiS. KonagaiN. AsanoR. YasudaS. Development of Pulmonary Arterial Hypertension in a Patient Treated with Qing-Dai (Chinese Herbal Medicine).Intern. Med.201958339539910.2169/internalmedicine.1523‑1830210129
    [Google Scholar]
  42. NishioM. HirookaK. DoiY. Chinese herbal drug natural indigo may cause pulmonary artery hypertension.Eur. Heart J.20163725199210.1093/eurheartj/ehw09026984865
    [Google Scholar]
  43. ChengX. AlborziniaH. MerzK.H. SteinbeisserH. MrowkaR. SchollC. KitanovicI. EisenbrandG. WölflS. Indirubin derivatives modulate TGFβ/BMP signaling at different levels and trigger ubiquitin-mediated depletion of nonactivated R-Smads.Chem. Biol.201219111423143610.1016/j.chembiol.2012.09.00823177197
    [Google Scholar]
  44. DamiensE. BaratteB. MarieD. EisenbrandG. MeijerL. Anti-mitotic properties of indirubin-3′-monoxime, a CDK/GSK-3 inhibitor: induction of endoreplication following prophase arrest.Oncogene200120293786379710.1038/sj.onc.120450311439342
    [Google Scholar]
  45. EricksonJ.C.III LauronF. Vasopressor effect of indigo carmine. A preliminary report.Guthrie J. Donald Guthrie Found. Med. Res.1960301303510.3138/guthrie.30.1.03013697121
    [Google Scholar]
  46. KawaiS. IijimaH. ShinzakiS. HiyamaS. YamaguchiT. ArakiM. IwataniS. ShiraishiE. MukaiA. InoueT. HayashiY. TsujiiM. MotookaD. NakamuraS. IidaT. TakeharaT. Indigo Naturalis ameliorates murine dextran sodium sulfate-induced colitis via aryl hydrocarbon receptor activation.J. Gastroenterol.201752890491910.1007/s00535‑016‑1292‑z27900483
    [Google Scholar]
  47. MontaniD. SavaleL. NataliD. JaïsX. HerveP. GarciaG. HumbertM. SimonneauG. SitbonO. Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension.Eur. Heart J.201031151898190710.1093/eurheartj/ehq17020543192
    [Google Scholar]
  48. RichS. KaufmannE. LevyP.S. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension.N. Engl. J. Med.19923272768110.1056/NEJM1992070932702031603139
    [Google Scholar]
  49. SitbonO. HumbertM. JaïsX. IoosV. HamidA.M. ProvencherS. GarciaG. ParentF. HervéP. SimonneauG. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension.Circulation2005111233105311110.1161/CIRCULATIONAHA.104.48848615939821
    [Google Scholar]
  50. MontaniD. LauE.M. DescathaA. JaïsX. SavaleL. AndujarP. Bensefa-ColasL. GirerdB. ZendahI. Le PavecJ. SeferianA. PerrosF. DorfmüllerP. FadelE. SoubrierF. SitbonO. SimonneauG. HumbertM. Occupational exposure to organic solvents: a risk factor for pulmonary veno-occlusive disease.Eur. Respir. J.20154661721173110.1183/13993003.00814‑201526541523
    [Google Scholar]
  51. SaleemiS. Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pulmonary hypertension associated with hemolytic anemia.Ann. Thorac. Med.201495Suppl. 16710.4103/1817‑1737.13403925077000
    [Google Scholar]
  52. HayesM.M. VedamurthyA. GeorgeG. DweikR. KlingsE.S. MachadoR.F. GladwinM.T. WilsonK.C. ThomsonC.C. Pulmonary hypertension in sickle cell disease.Ann. Am. Thorac. Soc.20141191488148910.1513/AnnalsATS.201408‑405CME25423000
    [Google Scholar]
  53. NissO. QuinnC.T. LaneA. DailyJ. KhouryP.R. BakeerN. KimballT.R. TowbinJ.A. MalikP. TaylorM.D. Cardiomyopathy With Restrictive Physiology in Sickle Cell Disease.JACC Cardiovasc. Imaging20169324325210.1016/j.jcmg.2015.05.01326897687
    [Google Scholar]
  54. DerchiG. GalanelloR. BinaP. CappelliniM.D. PigaA. LaiM.E. QuartaA. CasuG. PerrottaS. PintoV. MusallamK.M. ForniG.L. Prevalence and risk factors for pulmonary arterial hypertension in a large group of β-thalassemia patients using right heart catheterization: a Webthal study.Circulation2014129333834510.1161/CIRCULATIONAHA.113.00212424081970
    [Google Scholar]
  55. JaïsX. IoosV. JardimC. SitbonO. ParentF. HamidA. FadelE. DartevelleP. SimonneauG. HumbertM. Splenectomy and chronic thromboembolic pulmonary hypertension.Thorax200560121031103410.1136/thx.2004.03808316085731
    [Google Scholar]
  56. TeawtrakulN. JetsrisuparbA. PongudomS. SirijerachaiC. ChansungK. WanitpongpunC. FucharoenS. Epidemiologic study of major complications in adolescent and adult patients with thalassemia in Northeastern Thailand: the E-SAAN study phase I.Hematology2018231556010.1080/10245332.2017.135884528759343
    [Google Scholar]
  57. WuX. XuW. WangJ. TianX. TianZ. XuK. Clinical characteristics in lymphangioleiomyomatosis-related pulmonary hypertension: an observation on 50 patients.Front. Med.201913225926610.1007/s11684‑018‑0634‑z29675687
    [Google Scholar]
  58. BadeschD.B. RaskobG.E. ElliottC.G. KrichmanA.M. FarberH.W. FrostA.E. BarstR.J. BenzaR.L. LiouT.G. TurnerM. GilesS. FeldkircherK. MillerD.P. McGoonM.D. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry.Chest2010137237638710.1378/chest.09‑114019837821
    [Google Scholar]
  59. ScicchitanoP. DentamaroI. TunziF. RicciG. CarbonaraS. DevitoF. ZitoA. CiampolilloA. CicconeM.M. Pulmonary hypertension in thyroid diseases.Endocrine201654357858710.1007/s12020‑016‑0923‑826994930
    [Google Scholar]
  60. Diaz-GuzmanE. FarverC. ParambilJ. CulverD.A. Pulmonary hypertension caused by sarcoidosis.Clin. Chest Med.2008293549563, x10.1016/j.ccm.2008.03.01018539244
    [Google Scholar]
  61. SoubrierF. ChungW.K. MachadoR. GrünigE. AldredM. GeraciM. LoydJ.E. ElliottC.G. TrembathR.C. NewmanJ.H. HumbertM. Genetics and genomics of pulmonary arterial hypertension.J. Am. Coll. Cardiol.20136225Suppl.D13D2110.1016/j.jacc.2013.10.03524355637
    [Google Scholar]
  62. MorrellN.W. AldredM.A. ChungW.K. ElliottC.G. NicholsW.C. SoubrierF. TrembathR.C. LoydJ.E. Genetics and genomics of pulmonary arterial hypertension.Eur. Respir. J.2019531180189910.1183/13993003.01899‑201830545973
    [Google Scholar]
/content/journals/nemj/10.2174/0102506882331838241122172040
Loading
/content/journals/nemj/10.2174/0102506882331838241122172040
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test